Geron and Hong Kong's Biotechnology Research Corporation form strategic alliance for Telomerase activation therapies
TAT will be owned 50% by Geron and 50% by BRC, a company established by the Hong Kong University of Science and Technology (HKUST), Geron's research partner. Geron is contributing scientific leadership, development expertise, intellectual property and capital to the new company. BRC is also providing scientific leadership, a research team, capital and laboratory facilities.
"We are very pleased to announce this important strategic event," said David L. Greenwood, Geron's executive vice president. "We first initiated a scientific collaboration on telomerase activation with the Biotechnology Research Institute of HKUST in 2000. It was productive. Our teams have discovered two small molecule compounds that activate telomerase in human in vitro models of chronic and infectious diseases, including AIDS. The potential therapeutic opportunities are numerous and large. We, and our partner, agreed to create and capitalize a new company to aggressively pursue further research with the intent of developing the compounds into commercial products."
Most read news
Organizations
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.